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Abstract
Background: The disruption of intercellular adhesions is an important component of the acquisition of invasive
properties in epithelial malignancies. Alterations in the cell-cell adhesion complex, E-Cadherin/β -Catenin, have been
implicated in the oncogenesis of carcinomas arising from various anatomic sites and have been correlated with adverse
clinico-pathologic parameters. In this study, the authors investigated the immunohistochemical expression of E-Cadherin
and β -Catenin in a cohort of early stage cervical cancers to determine its prognostic significance and to investigate
differences between the three major histological subtypes.
Patients and methods: A tissue microarray of 147 cases of FIGO stage 1A and 1B cervical carcinomas [96 squamous
cell carcinomas (SCC), 35 adenocarcinomas (AC), 12 adenosquamous carcinomas (ASQ), 4 miscellaneous types] was
constructed from our archived surgical pathology files and stained with monoclonal antibodies to E-Cadherin and β -
Catenin. Cases were scored by multiplying the intensity of staining (1 to 3 scale) by the percentage of cells stained (0–
100%) for a potential maximum score of 300. For both markers, "preserved" expression was defined as bright
membranous staining with a score of 200 or above. "Impaired" expression included any of the following: negative staining,
a score less than 200, or exclusively cytoplasmic or nuclear delocalization.
Results: Impaired expression of β -Catenin was found in 85.7%, 66.7%, & 58.3% of AC, SCC & ASQ respectively.
Impaired expression of E-Cadherin was found in 94.3%, 86.5% & 100% of cases of AC, SCC, & ASQ respectively. The
differences between the histologic subtypes were not significant. For the whole cohort, a comparsion of cases showing
impaired versus preserved of E-Cadherin and β -Catenin expression showed no significant differences with respect to
recurrence free survival, overall survival, patient age, histologic grade, and frequency of lymphovascular invasion or lymph
node involvement. There was no correlation between the status of both markers for all three histological subtypes
(overall spearman correlation co-efficient r = 0.12, p = 0.14)
Conclusion: Impairment of E-Cadherin and β -Catenin expression is very frequent in early stage cervical cancers, and
alterations in the E-Cadherin/β -Catenin cell adhesion complex are therefore likely involved in the pathogenesis of
cervical carcinomas even at their earliest stages. None of the three major histological subtypes of cervical carcinoma
(SCC, ADCA, ADSQ) is significantly more likely than the others to show impairment in E-Cadherin and β -Catenin
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expression. Overall, the expression of both markers does not significantly correlate with clinico-pathological parameters
of prognostic significance.
Background
The resounding success of the routine papanicolaou
smear in reducing the incidence and mortality of cervical
cancer has been chronicled extensively [1-6]. However,
epidemiological data from 2004 indicates that 10,520
new cases of invasive cervical cancer are still diagnosed
annually in the United States, with an associated mortality
rate of approximately 37% [7]. For those patients with
early stage (FIGO stage I and II) cervical cancers treated
primarily with surgical therapy, the decision to administer
adjuvant therapy is dependent on a variety of clinical and
histopathological parameters. The latter includes the pres-
ence or absence of lymphovascular, or deep stromal inva-
sion, large tumor size, tumor involvement of resection
margins, involvement of regional lymph nodes etc [8].
Although histopathological parameters classify these
patients into broad groups – each comprised of patients
with similar risk-profiles for recurrence, the groupings are
inherently non-specific [9]. Therefore, it is anticipated
that some patients with cervical cancer receive unneces-
sary adjuvant therapy, with their attendant toxicities. It
would thus be of interest to identify biomarkers which
can be evaluated on the primary tumor and may further
help refine the subset of patients at the most significant
risk for recurrence and thus in need of intensive adjuvant
management.
The disruption of intercellular adhesions is an important
component of the acquisition of invasive properties in
epithelial malignancies. Alterations in the cell-cell adhe-
sion complex, E-Cadherin/β -Catenin, have been impli-
cated in the oncogenesis of carcinomas arising from
various anatomic sites and have been correlated with
adverse clinico-pathological parameters [10-22]. Epithe-
lial Cadherin (E-Cadherin) is a 120 kDa transmembrane
glycoprotein which is involved in both homotypic and
heterotypic Ca2+-dependent cellular adhesions [23-26].
Inactivation of E-Cadherin may occur through mutations,
methylations or deletions of the E-cadherin gene, suppres-
sion of the E-Cadherin gene promoter, or posttransla-
tional modification of the protein leading to cytoplasmic
delocalization [27-30]. The strength of E-Cadherin-medi-
ated intercellular adhesion is significantly increased by
interactions between the cytoplasmic tail of E-cadherin
and the cytoskeletal network [30]. This interaction is
mediated through the cytoplasmic proteins β -Catenin, α -
Catenin and γ -Catenin [23-26]. β -Catenin is a 92 kDa pro-
tein that, in addition to its cell-adhesion properties, also-
plays a role as a transcriptional co-activator in the Wnt
signaling pathway; the latter is involved in cellular devel-
opment, differentiation and oncogenesis [32,33]. Deregu-
lation of the Wnt  pathway may occur through an
activating mutation of the β -Catenin gene, leading to
accumulated levels of β -Catenin in the cytoplasm and
nucleus, and culminating in the altered transcription of a
variety of critical genes [26].
The cervix, in which a dysplasia-to-carcinoma sequence is
well-established, offers a useful medium to comparatively
study the expression of proteins involved in cell-to-cell
adhesion in dysplastic and invasive epithelium. Previous
studies have shown that the expression of E-Cadherin and
β -Catenin, as evaluated immunohistochemically, is
inversely proportional to the histologic grade in squa-
mous intraepithelial lesions (SIL) of the cervix: expression
of both markers is generally maintained in low-grade
lesions and is lost in high grade lesions [34-36]. In the
present study, the expression of E-Cadherin and β -Cat-
enin was evaluated on a cohort of already invasive, albeit
early stage cervical carcinomas. Our objectives are 1) to
determine the frequency of loss of expression of E-Cad-
herin and β -Catenin in early stage cervical carcinomas 2)
to determine whether the expression of either of these
biomarkers is of prognostic significance 3) to specifically
investigate whether there are any differences between the
three major histological subtypes of cervical carcinoma
with respect to expression of E-Cadherin and β -Catenin.
Patients and methods
Case selections and microarray construction
Following approval from our institutional review board, a
tissue microarray (TMA) [37] of 147 cases of international
federation of gynecology and obstetrics (FIGO) stage 1a
and 1b cervical carcinomas was constructed. Technical
details on microarray construction at the Yale tissue
microarray facility are outlined elsewhere [38,39]. The
cases were retrieved from the archived surgical pathology
files at Yale New Haven Hospital and consisted of carcino-
mas diagnosed between 1987 and 2001. These cases were
not consecutive but were selected on the basis of availabil-
ity of at least one evaluable tumor-representative hema-
toxylin and eosin-stained slide and a paraffin block. On
each case, slides were reviewed to select a representative
tumor spot. The corresponding spot on the associated par-
affin block was then cored and placed on a tissue microar-
rayer (Beecher Instruments, Silver Spring, MD, USA). The
microarray was constructed with a 2-fold redundancy (2
spots for each patient), which has been previously shown
by Camp et al [40] to accurately represent standard tissue
sections in at least 95% of cases. The finalized arrays wereWorld Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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then cut into 5 µm-thick sections and mounted on glass
slides using an adhesive tape-transfer system (Instrumed-
ics Inc., Hackensack, NJ, USA) with ultraviolet cross-link-
ing.
Normal controls
To evaluate the staining patterns of E-Cadherin and β -Cat-
enin in the normal cervix, 5 such cases were retrieved from
our database. These 5 cases were hysterectomies per-
formed for adnexal masses in which the final diagnoses
were non-neoplastic (endometriosis [n = 4], tubo-ovarian
abscess [n = 1]), Sections from the cervix in these cases
were then stained with monoclonal antibodies to E-Cad-
herin and β -Catenin.
Immunohistochemistry
The tissue microarray slides were stained with antibodies
to E-Cadherin (Clone NCH-38, dilution 1:100, DakoCy-
tomation Corporation, Carpinteria, CA, USA) and β -Cat-
enin (Clone 17C2, dilution 1:100, NovoCastra
Laboratories Ltd., Tyne, UK) using a DAKO autostainer
based on the standard avidin-biotin complex method. Tis-
sue microarray slides were deparaffinized with xylene and
graded alcohols then rehydrated with distilled water.
Endogenous peroxidase activity was blocked by placing
the slides in 0.5% hydrogen peroxidase/methanol for 10
minutes followed by a tap water rinse. Background stain-
ing was reduced by incubating slides in 0.3% bovine
serum albumin/Tris-buffered saline. Antigen retrieval
entailed placing the slides in a pressure cooker with an
antigen unmasking solution (0.01M citrate buffer, pH
6.0) for 1 minute. Slides were subsequently incubated
with the primary (4°C overnight), then biotinylated sec-
ondary antibodies and streptavidin-biotin peroxidase.
0.05% 3'3' diaminobenzidine (DAB) was used as chro-
mogen, followed by counterstaining with hematoxylin.
Scoring of immunohistochemical staining
Since both E-Cadherin and β -Catenin are normally
expressed in a bright membranous fashion in the cervical
epithelium, aberrations on this basic theme were deemed
abnormal for the purposes of this study. Thus, cytoplas-
mic staining, nuclear staining and no staining were con-
sidered "impaired" expression. Cases were scored by
multiplying the intensity of staining (1 to 3 scale, see fig-
ure 1) by the percentage of cells stained (0–100%) for a
potential maximum score of 300. For both markers, "pre-
served" expression was defined as bright membranous
staining with a score of 200 or above. "Impaired" expres-
sion included any of the following: negative staining, a
score less than 200, or exclusively cytoplasmic and/or
nuclear delocalization. Only the core showing the highest
score was utilized in each case. In 144 of 147 cases, the
scores did not differ between the 2 cores on each case by
more than 50 points. None of the 3 cases with such a dis-
crepancy (i.e. differences of more than 100 points
between the 2 cores) affected the "impaired" versus "pre-
served" expression distinction, because all 3 cases showed
impaired expression in both cores. The microarrays were
scored by 2 independent observers (OF and DH). Discrep-
ancies were resolved at a consensus session. Results were
then correlated with a variety of pathologic parameters,
including tumor size, frequency of lymphovascular inva-
sion, lymph node involvement and histological grade.
Statistical analysis
For comparison of cases showing impaired versus pre-
served expression with respect to various clinico-patho-
logical parameters, two-sided likelihood ratio chi-square
test or Fisher's exact tests were used with p < 0.05 as the
"statistically significant" cut-off point. Survival analysis
was carried out by Kaplan-Meier method and Wilcoxon
test was used to compare survival. Spearman correlation
coefficients were calculated to examine the correlations
between the two markers. All analyses were performed
using SAS version 9.0 (SAS Institute, NC).
Validation
To externally validate the staining patterns observed on
the microarray, 14 cases representing approximately 10%
of the array were selected in a semi-random fashion using
a randomization function (Microsoft Excel®, Microsoft
Inc, Redmond, WA, USA) on a list of the entire cohort.
The goal was to obtain a representative mix of cases with
negative and positive stainings (4 groups, each consisting
of 3 cases with a score of 0, 1–99, 100–199, 200–300; 2
additional cases for the last group). Thus, each case
selected from the list by the randomization function was
included in the validation list consecutively until the pre-
set quantitative requirement for that group was met. On
each of these 14 cases, a full representative tissue section
was then stained with E-Cadherin and β -Catenin and
scored using the same system used with the microarray.
Results
Normal epithelium
The staining patterns of E-Cadherin and β -Catenin were
identical. However, β -Catenin staining was generally of
greater intensity than E-Cadherin staining. In the endocer-
vices of all 5 cases, both markers brightly decorated the
epithelium in a circumferentially membranous fashion
(basolateral and glycocalyceal). No cytoplasmic or
nuclear staining was noted (Figures 2a and 2b). In the
ectocervix, staining was also membranous but was limited
to the lower two-thirds in 4 cases and the lower half in 1
case (Figure 2c). Squamous metaplastic epithelium was
present in 3 cases, all of which showed transmural bright
membranous staining (Figure 2d). In all 5 cases, the basal
and parabasal cells displayed the greatest intensity of
staining (3/3). There was no stromal staining.World Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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Tissue microarray
The 147 cases consisted of 96 squamous cell carcinomas
(SCC), 35 adenocarcinomas (ADCA), 12 adenosquamous
carcinomas (ADSQ) and a heterogeneous group of 4 cases
hereafter referred to as "others". The latter group included
1 small cell carcinoma, 1 pure large cell neuroendocrine
carcinoma, 1 squamotransitional carcinoma and 1 ade-
nosquamous carcinoma with morphologically-evident
neuroendocrine differentiation. 4 cases were deemed
unsatisfactory during scoring by virtue of poor tissue pres-
ervation on the microarray slides. The clinicopathological
characteristics of the cohort are outlined in table 1.
β -Catenin
Impaired expression of β -Catenin was present in 107
(75%) of the 143 cases and in the majority of all the his-
tological subtypes. ADCA had the highest percentage of
impaired beta-catenin expression (85.7%, 30/35). Com-
pared to ADCA, a smaller proportion of cases of SCC
showed impaired beta-catenin expression (66.7%, 64/
96). However, the difference was not significant (p =
0.06). ADSQ showed an even lower proportion of cases
with impaired beta-catenin expression (58.3%, 7/12).
Compared to ADCA, the difference was not significant (p
= 0.06). The difference between SCC and ADSQ was also
not significant (p = 0.47). Impairment of expression was
most commonly in the form of absent staining (79/107);
19 cases did not meet out quantitative criteria for positiv-
ity while 5 cases showed exclusively cytoplasmic delocali-
zation. There were no cases of exclusively nuclear staining
(Table 2). The mean age for the patients with preserved
and impaired β -Catenin expression was 41.5 years (±
10.6) (n = 39) and 41.6 years (± 11.5) (n = 104) respec-
tively. There was no significant difference (p = 0.99)
Representative cores illustrating the criteria used for scoring staining intensity (β -Catenin is shown; E-Cadherin was similar,  although with an overall lower intensity) Figure 1
Representative cores illustrating the criteria used for scoring staining intensity (β -Catenin is shown; E-Cadherin was similar, 
although with an overall lower intensity).World Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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between these 2 groups. Similarly, there were no statisti-
cally significant differences with respect to recurrence free
survival (Figure 3), overall survival (Figure 4), frequency
of lymphovascular invasion, histologic grade, and fre-
quency of lymph node involvement (Table 3) when cases
with impaired expression of β -Catenin were compared
with those in which β -Catenin was preserved.
E-Cadherin
Of the 143 cases, 134 (94%) showed impaired expression
of E-Cadherin. Notably, impaired expression of E-Cad-
herin was present in 100% of the 12 ADSQ; however, high
frequencies of impaired expression were also present in
ADCA and SCC and the differences between the histologic
subtypes were not statistically significant. Impairment of
expression was most commonly in the form of absent
staining (99/134); 24 cases did not meet out quantitative
criteria for positivity while 8 cases showed exclusively
cytoplasmic delocalization. No case showed nuclear stain-
ing (Table 2). The mean age for the patients with pre-
served and impaired E-Cadherin expression was 36.5
years (± 9.1) (n = 12) and 42.4 years (± 11.7) (n = 131)
respectively. Thus, patients with impaired E-Cadherin
expression appeared to be older than patients with pre-
served E-Cadherin expression. However, the difference
was not statistically significant (p = 0.09). As with β -Cat-
enin, there were no statistically significant differences
with respect to recurrence free survival (Figure 3), overall
Expression of E-Cadherin in the normal endocervix (2a, hematoxylin and eosin, original magnification ×100; 2b: hematoxylin  and eosin, original magnification ×200), ectocervix (2c: hematoxylin and eosin, original magnification ×100) and squamous  metaplastic epithelium at the transformation zone (2d) (hematoxylin and eosin, original magnification ×200) Figure 2
Expression of E-Cadherin in the normal endocervix (2a, hematoxylin and eosin, original magnification ×100; 2b: hematoxylin 
and eosin, original magnification ×200), ectocervix (2c: hematoxylin and eosin, original magnification ×100) and squamous 
metaplastic epithelium at the transformation zone (2d) (hematoxylin and eosin, original magnification ×200).World Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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survival (Figure 4), frequency of lymphovascular inva-
sion, lymph node involvement and histologic grade
(Table 3) when cases with impaired expression of E-Cad-
herin were compared with those in which E-Cadherin was
preserved.
β -Catenin and E-Cadherin correlation analysis
Only six (4%) of 143 cases showed preservation of both E-
Cadherin and β -Catenin expression and 93 (65%) of 143
cases showed impairment in the expression of both mark-
ers, 7 cases showed impairment in β -Catenin and preser-
vation of E-Cadherin whereas the reverse was observed in
34 cases. Overall, the expressions of E-Cadherin and β -
Catenin were not significantly correlated (spearman cor-
relation coefficient r = 0.12, p = 0.14). Similar findings
were noted when each of the 3 major histological sub-
types was subjected to the same analysis (table 4)
Validation
In 13 of 14 cases, the scores obtained on standard histo-
logic sections were within 50 points of the scores obtained
on the corresponding tissue microarray spot (average dif-
ference: 30). In the 14th case, the tissue microarray spot
was scored 0 whereas the corresponding histologic section
was scored 100. In none of the 14 cases did a score dis-
crepancy affect the "preserved" versus "impaired"
distinction.
Table 1: Summary of Clinical and Pathological characteristics of 
Cohort
Clinicopathologic Parameter n
Age (years) Median 40
Mean 42
Range 20–77
FIGO stage 1A1 14
1A2 15
1B1 109
1B2 9
Lymphovascular invasion Present 62
Absent 85
Histological grade 13 3
25 4
36 0
Lymph node involvement Present 18
Absent 129
Tumor Size (cm) 0.1–0.5 44
0.6–1.0 28
1.1–2.0 33
2.1–3.0 21
>3.1 21
Follow-up (years) Median 4.75
Mean 5.84
Range 0.12–17.43
FIGO: International Federation of Gynecology and Obstetrics
Table 2: Number of patients expressing E-Cadherin and β -Catenin among the various histologic subtypes
Histologic subtype of cervical carcinoma Preserved¶ Impaired U
Reduced 
Staining ▼
Exclu-Sively 
Cyto-Plasmic 
Stain Ing
Negative 
Staining
Nuclear 
Staining
β -catenin expression
Squamous cell Carcinoma (n = 96) 29 10 2 52 0 3
Adenocarcinoma (n = 35) 57 1 2 2 0 0
Adenosquamous (n = 12) 51 2 4 0 0
Others (n = 4) 11 0 1 0 1
Total (n = 147) 40 19 5 79 0 4
E-cadherin expression
Squamous cell Carcinoma (n = 96) 11 16 2 65 0 2
Adenocarcinoma (n = 35) 15 3 2 5 0 1
Adenosquamous (n = 12) 03 2 7 0 0
Others (n = 4) 10 1 2 0 0
Total (n = 147) 13 24 8 98 0 4
U: unsatisfactory
¶ membranous staining with 200 score or higher
▼ less than 200 scoreWorld Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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Discussion
In this study, we demonstrate that 1) loss of expression of
both E-Cadherin and β -Catenin are frequent events in
early stage cervical carcinomas of all three major histolog-
ical subtypes, and both proteins are thus likely partici-
pants in the pathogenesis of cervical carcinoma, 2) Loss of
expression of both proteins is of no prognostic signifi-
cance with respect to the following parameters: recurrence
free survival, overall survival, frequency of lymphovascu-
lar invasion, histologic grade, and frequency of lymph
node involvement. Our findings are in concordance with
the recent study of Van de Putte et al [41], in which cases
of stage 1B SCC were analyzed. In that study, loss of
expression of E-Cadherin and β -Catenin in greater than
50% of tumor cells was found in 90% and 72% of cases
respectively. However, the authors found no correlation
between the expression of E-Cadherin and β -Catenin (and
other catenins) and prognosis [41]. In contrast, Jeffers et al
[42] found strong expression of E-Cadherin in all 20 cases
of invasive cervical carcinoma that were studied. How-
ever, those 20 cases were an admixture of all stages and the
prognostic significance of E-Cadherin was not specifically
investigated since all cases were positive. Other studies
have also showed a high frequency of loss of E-Cadherin
expression in cervical cancers. Applying the criteria of the
present study, impaired expression of E-cadherin was
found in 89% of invasive SCCs in one study [34]. In the
study of Sun et al [43], 60 cases of invasive cervical carci-
noma of all stages were investigated for E-cadherin expres-
sion. Loss of expression of E-Cadherin was found in
53.3% of cases. Additionally, the authors found a correla-
tion between abnormal E-Cadherin expression and clini-
cal stage and, in contrast to the present study, lymph node
involvement and histologic grade. Similarly, among all
stages of cervical adenocarcinoma, abnormal expression
Kaplan-Meier recurrence-free survival curves comparing  patients whose cervical carcinomas showed preserved  expression of E-Cadherin and β -Catenin to those with  impaired expression (▲  indicates censored observations) Figure 3
Kaplan-Meier recurrence-free survival curves comparing 
patients whose cervical carcinomas showed preserved 
expression of E-Cadherin and β -Catenin to those with 
impaired expression (▲  indicates censored observations).
Kaplan-Meier overall survival curves comparing patients  whose cervical carcinomas showed preserved expression of  E-Cadherin and β -Catenin to those with impaired expression  (▲  indicates censored observations) Figure 4
Kaplan-Meier overall survival curves comparing patients 
whose cervical carcinomas showed preserved expression of 
E-Cadherin and β -Catenin to those with impaired expression 
(▲  indicates censored observations).World Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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of β -Catenin was significantly associated with advanced
pathologic stage and thus disease-free survival in another
study [44]. In the latter two studies, the noted discrepan-
cies with the current one may be related to qualitative
technical differences (antibody concentration, antigen
retrieval methods etc) or differences in interpretation (i.e.
criteria for positivity). None of the above studies have spe-
cifically compared the 3 major histologic subtypes in early
stage cervical carcinoma. However, the majority of studies
show that loss of expression of E-Cadherin and β -Catenin
is frequent in cervical carcinomas. Although their impact
on prognosis of this expression is less certain, our study
finds that the expression of both E-Cadherin and β -Cat-
enin lacks prognostic significance at least in early stage
cervical carcinoma.
An orderly, membranous expression of E-Cadherin and β -
Catenin is found in the normal cervix. The loss of expres-
sion of both proteins in a high proportion of high-grade
squamous intraepithelial lesions [34-36] suggests that
dysregulation of this pathway is an early event in cervical
carcinogenesis. We investigated cytoplasmic and nuclear
Table 3: Lack of association between expression of E-Cadherin or β -Catenin and lymphovascular invasion, frequency of lymph node 
involvement or histologic grade
Preserved¶ Impaired
Reduced 
Staining ▼
Exclusively 
Cytoplasmic 
Staining
Negative 
Staining
Nuclear 
Staining
p value 
(impaired 
versus 
preserved 
expression)
1) Lymphovascular invasion
β -Catenin expression
Absent (n = 83) 20 7 2 54 0 0.4
Present (n = 60) 20 12 3 25 0
E-Cadherin expression
Absent (n = 83) 6 11 3 63 0 0.4
Present (n = 60) 7 13 5 35 0
2) Histological grade*
β -Catenin expression
1 (n = 31) 8 3 1 19 0 >0.05 for all 
comparisons
2  ( n  =  5 3 )2 07 12 50
3  ( n  =  5 9 )1 29 33 50
E-Cadherin expression
1 (n = 31) 1 5 2 23 0 >0.05 for all 
comparisons
2 (n = 53) 4 13 3 33 0
3  ( n  =  5 9 )863 4 2 0
3) Lymph node Involvement
β -Catenin expression
Absent (n = 125) 33 15 5 72 0 0.3
P r e s e n t  ( n  =  1 8 ) 74070
E-Cadherin expression
Absent (n = 125) 9 21 7 88 0 0.06
Present (n = 18) 4 3 1 10 0
¶ membranous staining with 200 score or higher
▼ less than 200 scoreWorld Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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staining as a manifestation of impaired expression of both
E-Cadherin and β -Catenin [26]. In the typical normal cell
β -Catenin's complex with E-Cadherin and the cytoskeletal
network is inversely proportional to the association of β -
Catenin with the adenomatous polyposis coli protein, a
large multifunctional cytosolic protein. Thus, normally,
only small portions of β -Catenin are found in the cyto-
plasm since the association of β -Catenin with APC
eventuates in its lytic degradation. Cytoplasmic accumula-
tion often leads to nuclear accumulation, where β -Cat-
enin may interact with a variety of proteins, culminating
in transcriptional activation of a variety of critical genes
[23-26]. Experimental studies have shown that tyrosine
phosphorylation of β -Catenin by oncogenic products or
growth factor receptors may cause dissociation of the E-
Cadherin-associated adhesion complex from the cytoskel-
eton resulting in cellular (non-membranous) redistribu-
tion and disassociation of adherens junctions, a well-
known feature of epithelial malignancies [45,46]. Exclu-
sively cytoplasmic localization of β -Catenin and E-Cad-
herin, which was not present in any of the normal cervix
epithelia, was seen in 3.4% and 5.4% of our carcinoma
cases respectively. A progressive increase in the proportion
of cases showing this finding was found in low grade SIL,
high grade SIL and invasive carcinomas in one study [34].
However, the logical extension of that finding, a
correlation with histological grade in invasive carcinomas,
was not found in this study. Our study is also in concord-
ance with that of Shinohara et al [47], in which no rela-
tionship was found between the frequency of
cytoplasmic/nuclear localization of β -Catenin and histo-
logic grade (no cases of nuclear localization β -Catenin
was found in our study).
The possibility that our findings may have been signifi-
cantly affected by our methods cannot be entirely
excluded. Tissue microarray technology as a high
throughput modality has gained wide acceptance in
pathology investigations and is used routinely [48-52].
Our TMA was constructed with a two-fold redundancy to
minimize sampling errors [40]. Furthermore, in our vali-
dation set which constituted approximately 10% of the
TMA, no significant discrepancies were seen. Nonetheless,
error introduced by tumor heterogeneity remains a possi-
bility. Most notably, the minimization of errors from the
redundant (2-fold) construction of our TMA presumes a
similar degree of tumor heterogeneity between breast [40]
and cervical cancer, which may be untrue.
The importance of defining thresholds in any investiga-
tions reporting the loss of the immunohistochemical
expression of a biomarker cannot be overemphasized. As
previously noted, a threshold of 200 was used in this
study because both E-Cadherin and β -Catenin are nor-
mally expressed in a membranous fashion in most of the
cervical epithelium (scores 270–300 for the ectocervix
and 300 for the endocervix). However, we performed sep-
arate statistical analyses when the threshold was lowered,
i.e. when "impaired" expression included any of the fol-
lowing: negative staining, a score less than 99, or exclu-
sively cytoplasmic and/or nuclear delocalization. The
results on all previous analyses remained the same (p >
0.05), with 2 exceptions: 1) Overall, the expressions of E-
Cadherin and β -Catenin became significantly correlated
(spearman correlation coefficient r = 0.33, p = 0.0001). 2)
73% of LVI-negative carcinomas showed impaired β -Cat-
enin expression, compared to 47% of LVI-positive carci-
nomas (p = 0.03). The significance of the latter finding is
unclear, and it can be anticipated that changes in the
threshold in either direction (lowering or raising) would
result in at least one parameter attaining statistical signif-
icance with each change. In our opinion, for a marker that
is normally expressed, a high threshold should be used for
"loss" of expression, and 200/300 seems reasonable.
Table 4: Lack of correlation between E-Cadherin and β -Catenin expression among the 3 major histologic subtypes of invasive 
carcinoma
Histological 
Subtype
E-Cadherin expression Correlation
Preserved Impaired
β -Catenin 
expression
Squamous cell 
carcinoma
Preserved 52 4
Impaired 6 56 r = 0.11 p = 0.3
Adenocarcinoma Preserved 05
Impaired 1 28 r = -0.07 p = 0.7
Adenosquamous 
carcinoma
Preserved 05
Impaired 0 7 Not applicableWorld Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
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Conclusion
In the present report we demonstrated that impairment of
E-Cadherin and β -Catenin expression is very frequent in
early stage cervical cancers. None of the three major histo-
logical subtypes of cervical carcinoma (SCC, ADCA,
ADSQ) is significantly more likely than the others to show
impairment in E-Cadherin and β -Catenin expression.
Alterations in the E-Cadherin/β -Catenin cell adhesion
complex are therefore likely involved in the pathogenesis
of cervical carcinomas even at their earliest stages. How-
ever, the expression of both markers does not significantly
correlate with clinicopathologic parameters of prognostic
significance.
Competing Interests
The author(s) declare that they have no competing
interests.
Authors' Contributions
OF wrote the initial version of the manuscript
HR collected clinical data and summarized clinicopatho-
logic information
JW performed statistical analysis and helped summarize
clinicopathologic information
DH and OF scored the tissue microarray
WZ and PES conceived of, supervised, and sponsored the
project. Both revised the manuscript.
All authors have read and approved the final manuscript
Acknowledgements
This study was presented in part at the 94th annual meeting of the United 
States and Canadian Academy of Pathology, Feb 26th – March 3rd, 2005, 
San Antonio, TX, USA
References
1. Koss LG: The Papanicolaou test for cervical cancer detection:
a triumph and tragedy.  JAMA 1989, 261:737-743.
2. van de Graaf Y, Vooijs GP, Zielhuis GA: Cervical screening
revisited.  Acta Cytol 1990, 34:366-372.
3. Devesa SS, Young JL Jr, Brinton LA, Fraumeni JF Jr: Recent trends
in cervix uteri cancer.  Cancer 1989, 64:2184-2190.
4. Wingo PA, Cardinez CJ, Landis SH, Greenlee RT, Ries LA, Anderson
RN, Thun MJ: Long-term trends in cancer mortality in the
United States, 1930–1998.  Cancer 2003, 97(suppl
12):3133-3275.
5. Adami HO, Ponten J, Sparen P, Bergstrom R, Gustafsson L, Friberg
LG: Survival trend after invasive cervical cancer diagnosis in
Sweden before and after cytologic screening, 1960–1984.
Cancer 1994, 73:140-147.
6. Benedet JL, Anderson GH, Matistic JP: A comprehensive program
for cervical cancer detection and management.  Am J Obstet
Gynecol 1992, 166:1254-1259.
7. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer
EJ, Thun MJ: Cancer Statistics, 2004.  CA Cancer J Clin 2004,
54:8-29.
8. Schilder JM, Stehman FB: Stage Ia-IIa cancer of the cervix.  Cancer
J 2003, 9:395-403.
9. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ:
A randomized trial of pelvic radiation therapy versus no fur-
ther therapy in selected patients with stage IB carcinoma of
the cervix after radical hysterectomy and pelvic lym-
phadenectomy: A Gynecologic Oncology Group Study.  Gyne-
col Oncol 1999, 73:177-183.
10. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K,
Debruyne FM, Bringuier PP: Prognostic value of cadherin-associ-
ated molecules (α -, β -, and γ -catenins and p120cas) in bladder
tumors.  Cancer Res 1996, 56:4154-4158.
11. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers
ED, Dinjens WN, Bosman FT: Reduced expression of the cad-
herin-catenin complex in esophageal adenocarcinoma cor-
relates with poor prognosis.  J Pathol 1997, 182:331-338.
12. van der Wurff AA, Vermeulen SJ, van der Linden EP, Mareel MM, Bos-
man FT, Arends JW: Patterns of α -and β -catenin and E-cad-
herin expression incolorectal adenomas and carcinomas.  J
Pathol 1997, 182:325-330.
13. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov
S, Van Roy F, Cornelisse CJ, Cleton-Jansen AM: Simultaneous loss
of E-cadherin and catenins in invasive lobular breast cancer
and lobular carcinoma in situ.  J Pathol 1997, 183:404-411.
14. Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne
FM, Oosterwijk E, Schalken JA: Decreased expression of alpha-
catenin is associated with poor prognosis of patients with
localized renal cell carcinoma.  Int J Cancer 1997, 74:523-528.
15. Zheng Z, Pan J, Chu B, Wong YC, Cheung AL, Tsao SW: Down reg-
ulation and abnormal expression of E-cadherin and β -catenin
in nasopharyngeal carcinoma: Close association with
advanced disease stage and lymph node metastasis.  Hum
Pathol 1999, 30:458-466.
16. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G: A causal role
for E-cadherin in the transition from adenoma to carcinoma.
Nature 1998, 392:190-191.
17. Jawhari AU, Noda M, Farthing MJ, Pignatelli M: Abnormal expres-
sion and function of the E-cadherin-catenin complex in gas-
tric carcinoma cell lines.  Br J Cancer 1999, 80:322-330.
18. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jen-
nings TA, Ingle R, Kim DN: E-cadherin expression in prostatic
carcinoma biopsies: Correlation with tumor grade, DNA
content, pathologic stage, and clinical outcome.  Mod Pathol
1994, 7:835-841.
19. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oost-
erhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin
expression is associated with poor prognosis in patients with
prostate cancer.  Cancer Res 1994, 54:3929-3933.
20. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS: Loss of β -
Catenin is associated with poor survival in ovarian
carcinomas.  Int J Gynecol Pathol 2004, 23:337-346.
21. Li Z, Ren Y, Lin SX, Liang YJ, Liang HZ: Association of E-cadherin
and beta-catenin with metastasis in nasopharyngeal
carcinoma.  Chin Med J 2004, 117:1232-1239.
22. Chang HJ, Jee CD, Kim WH: Mutation and altered expression of
beta-catenin during gallbladder carcinogenesis.  Am J Surg
Pathol 2002, 26:758-766.
23. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev : The cadherin-catenin
adhesion system in signaling and cancer.  J Clin Invest 2002,
109:987-991.
24. Gooding JM, Yap KL, Ikura M: The cadherin-catenin complex as
a focal point of cell adhesion and signaling: new insights from
three-dimensional structures.  BioEssays 2004, 26:497-511.
25. Nelson WJ, Nusse R: Convergence of Wnt, β -Catenin, and
Cadherin pathways.  Science 2004, 303:1483-1487.
26. Hajra KM, Fearon ER: Cadherin and Catenin alterations in
human cancer.  Genes, Chromosomes Cancer 2002, 34:255-268.
27. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M,
Cornelisse C, van Roy F: E-cadherin is a tumour/invasion sup-
pressor gene mutated in human lobular breast cancers.
EMBO J 1995, 14:6107-6115.
28. Vos CB, Cleton-Jansen AM, Berx G, de Leeuw WJ, ter Haar NT, van
Roy F, Cornelisse CJ, Peterse JL, van de Vijver MJ: E-cadherin inac-
tivation in lobular carcinoma in situ of the breast: an early
event in tumorigenesis.  Br J Cancer 1997, 76:1131-1133.
29. Nawrocki B, Polette M, Van Hengel J, Tournier JM, Van Roy F, Birem-
bault P: Cytoplasmic redistribution of E-cadherin-catenin
adhesion complex is associated with down-regulated tyro-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
World Journal of Surgical Oncology 2005, 3:38 http://www.wjso.com/content/3/1/38
Page 11 of 11
(page number not for citation purposes)
sine phosphorylation of E-cadherin in human bronchopulmo-
nary carcinomas.  Am J Pathol 1998, 153:1521-1530.
30. Hirohashi S: Molecular aspects of adhesion-epigenetic mecha-
nisms for inactivation of the E-Cadherin-mediated cell adhe-
sion system in cancers.  Verh Dtsch Ges Pathol 2000, 84:28-32.
31. Yap AS, Brieher Wm, Pruschy M, Grumbiner WM: Lateral cluster-
ing of the adhesive ectodomain: a fundamental determinant
of Cadherin function.  Curr Biol 1997, 7:308-315.
32. Miller JR, Hocking AM, Brown JD, Moon RT: Mechanism and func-
tion of signal transduction by the Wnt/beta-Catenin and
Wnt/Ca2+ pathways.  Oncogene 1999, 18:7860-7872.
33. Peifer M, Polakis P: Wnt signaling in oncogenesis and embryo-
genesis-a look outside the nucleus.  Science 2000,
287:1606-1609.
34. Faleiro-Rodrigues C, Lopes C: E-cadherin, CD44 and CD44v6 in
squamous intraepithelial lesions and invasive carcinomas of
the uterine cervix: an immunohistochemical study.  Pathobiol-
ogy 2004, 71:329-336.
35. de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, War-
naar SO, Fleuren GJ, Litvinov SV: Changing roles of cadherins and
catenins during progression of squamous intraepithelial
lesions in the uterine cervix.  Am J Pathol 1999, 155:505-515.
36. Yang JZ, Zhang XH, Wu WX, Yan X, Liu YL, Wang JL, Wang FR:
Expression of EP-CAM, beta-catenin in the carcinogenesis of
squamous cell carcinoma of uterine cervix.  Zhonghua Zhong Liu
Za Zhi 2003, 25:372-375.
37. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P,
Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue
microarrays for high-throughput molecular profiling of
tumor specimens.  Nat Med 1998, 4:844-847.
38. Charette L, Rimm DL: Yale tissue microarray construction pro-
tocols. Version 1.0, 1/2001.   [http://tissuearray.org/yale/tisar
ray.html. Accessed 02/20/05].
39. Rimm DL, Camp RL, Charette LA, Olsen DA, Provost E: Amplifica-
tion of tissue by construction of tissue microarrays.  Exp Mol
Pathol 2001, 70:255-264.
40. Camp RL, Charette LA, Rimm DL: Validation of tissue microar-
ray technology in breast carcinoma.  Lab Invest 2000,
80:1943-1949.
41. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R: E-
cadherin and catenins in early squamous cervical carcinoma.
Gynecol Oncol 2004, 94:521-527.
42. Jeffers MD, Paxton J, Bolger B, Richmond JA, Kennedy JH, McNicol
AM: E-cadherin and integrin cell adhesion molecule expres-
sion in invasive and in situ carcinoma of the cervix.  Gynecol
Oncol 1997, 64:481-486.
43. Sun H, Liu X, Li M: E-cadherin expression and its clinical signif-
icance in cervical cancer.  Zhonghua Zhong Liu Za Zhi 2000,
22:496-498.
44. Imura J, Ichikawa K, Takeda J, Fujimori T: Beta-catenin expression
as a prognostic indicator in cervical adenocarcinoma.  Int J Mol
Med 2001, 8:353-358.
45. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM,
Birchmeier W: Loss of epithelial differentiation and gain of
invasiveness correlates with tyrosine phosphorylation of the
E-cadherin/beta-catenin complex in cells transformed with a
temperature-sensitive v-SRC gene.  J Cell Biol 1993,
120:757-766.
46. Aberle H, Schwartz H, Kemler R: Cadherin-catenin complex:
protein interactions and their implications for cadherin
function.  J Cell Biochem 1996, 61:514-523.
47. Shinohara A, Yokoyama Y, Wan X, Takahashi Y, Mori Y, Takami T,
Shimokawa K, Tamaya T: Cytoplasmic/nuclear expression with-
out mutation of exon 3 of the beta-catenin gene is frequent
in the development of the neoplasm of the uterine cervix.
Gynecol Oncol 2001, 82:450-455.
48. Henshall S: Tissue microarrays.  J Mammary Gland Biol Neoplasia
2003, 8:347-358.
49. Hsu FD, Nielsen TO, Alkushi A, Dupuis B, Huntsman D, Liu CL, van
de Rijn M, Gilks CB: Tissue microarrays are an effective quality
assurance tool for diagnostic immunohistochemistry.  Mod
Pathol 2002, 15:1374-1380.
50. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M: Tis-
sue microarray: a new technology for amplification of tissue
resources.  Cancer J 2001, 7:24-31.
51. van de Rijn M, Gilks CB: Applications of microarrays to
histopathology.  Histopathology 2004, 44:97-108.
52. DiVito KA, Charette LA, Rimm DL, Camp RL: Long-term preser-
vation of antigenicity on tissue microarrays.  Lab Invest 2004,
84:1071-1078.